Table 7 ICI discontinuation
From: Ocular adverse events associated with immune checkpoint inhibitors, a scoping review
| Â | Cases ICI discontinued |
|---|---|
Uveitis (n = 134) | 79 (59.0%) |
Neuro-ophthalmic disordes (n = 71) | 53 (74.6%) |
Orbit and ocular adnexa (n = 33) | 23 (69.7%) |
Cornea and ocular adnexa (n = 30) | 20 (66.7%) |
Retina (n = 26) | 16 (61.5%) |